Lee Goldstein, MD/Ph.D.
Associate Professor, Biomedical Engineering
Associate Professor, Psychiatry, Neurology, Opthalmology, Pathology and Laboratory Medicine
Director, Molecular Aging and Development Laboratory
Director, Translation Core, NIH Alzheimer’s Disease Center
Director, Center for Biometals & Metallomics (CBM)
Director, Molecular Biophotonics Laboratory (MBL)
Phone: (617) 414-8361
Offices: Medical Center: 670 Albany St., 4th Floor, Boston, MA 02118;
Photonics Center: PC-727, 8 St. Mary’s St., Boston, MA 02215
Dr. Goldstein is a Phi Beta Kappa graduate of Columbia University and received M.D. and Ph.D. (Neuroscience) degrees from Yale University. He completed clinical fellowship training in psychiatry at the Massachusetts General Hospital, Harvard Medical School, where he also conducted postdoctoral research in Alzheimer’s disease with Rudolph Tanzi, Ph.D. and Ashley Bush, M.D., Ph.D. at the Genetics and Aging Research Unit. In 2001, Dr. Goldstein moved to the Brigham & Women’s Hospital where he established an independent laboratory as a Beeson Scholar in Aging Research and Assistant Professor in Psychiatry at Harvard Medical School. The research team was recently recruited to Boston University and moved to new laboratories at Boston Medical Center and the Boston University Photonics Center in 2008. He is Founding Scientist and Chairman, Science Advosry Board, at Neuroptix, a leading innovator in laser-based molecular diagnostics and ophthalmic instrumentation.
Laser Diagnostics; Experimental Pathology; Translational Neuroscience; Molecular Biology, Biophotonics; Radiobiology; Biometallomics; Alzheimer’s Disease; Down Syndrome; Neurodegeneration; Cataracts; Molecular Aging; Ethnopharmacology.
Dr. Goldstein’s work is focused on understanding the role of abnormal protein aggregation in chronic degenerative disorders of aging. Major laboratory research thrusts include Alzheimer’s disease, Down syndrome, age-related cataracts, radiobiology, molecular aging, and biometallomics. His team recently discovered the first evidence of Alzheimer’s disease-associated amyloid pathology outside the brain (Lancet, 2003) as well as a new transcription factor that plays a crucial role in cellular differentiation within the lens and brain. He and his laboratory are developing a laser-based diagnostic technology to detect Alzheimer’s disease years before the first symptoms emerge. Allied technology under development in the laboratory target molecular pathology in Down syndrome, age-related and radiogenic cataracts, diabetes mellitus, and molecular aging. Biophotonic tools are also developed and deployed to investigate primary mecahnisms underpinning pathogenic protein aggregation. The laboratory is also pioneering new technology for metallomic imaging mass spectrometry (MIMS) to explore the human metallome in health and disease.
Selected Recent Publications
Soscia SJ, Kirby JE, Tucker SM, Washicosky KJ, Hyman BH, Burton MA, Goldstein LE, Duong S, Moir RD, Tanzi RE. “The Alzheimer’s disease amyloid ß-peptide is an antimicrobial peptide” PLoS One 5(3): e9505. (2010)
Goldstein LE, et al. “Method diagnosing neurodegenerative disease” US Patent 7,653,428. (2010)
Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Bush AI. “Cytosolic ß-amyloid deposition & supranuclear cataracts in lenses from people with Alzheimer’s disease“ Lancet. 361:1258-65. (2003)
Moncaster JA, Pineda R, Moir RM, Lu S, Burton M, Ghosh J, Ericsson M, Soscia SS, Mocofanescu A, R. Folkerth R, Robb RM, Clark JI, Tanzi RE, Hunter DG, Goldstein LE. “Alzheimer’s disease ß-amyloid and supranuclear cataracts in lenses from people with Down syndrome” (Pending)